DMTX News

AveXis, an early-stage biotech developing gene therapies for rare neurological diseases, announced terms for its IPO on Monday. The Bannockburn, IL-based company plans to raise $85 million by offering 4.25 million shares at a price range of $19 to $21. Insiders intend to purchase $30 million worth of shares in the offering. At the midpoint of the proposed range, AveXis would...read more

A bad start to the year only got worse this week as the S&P 500 fell another 2%. For the first time since October, the ninety-day returns swung negative to -0.6%. Just two weeks ago, that number stood at 17%. The VIX is up 48% year-to-date, closing Friday at 27. After 12 companies submitted their initial filings with the SEC in the first week of the year, just three...read more

Pricing pressure continued this week as only one company was able to price in or above its range. Five IPOs raised $1.2 billion this week, including one of the most highly-anticipated IPOs of 2015. However, it was a global print packaging manufacturer that had the best IPO. Two biotechs and a REIT specializing in farmland went public this week as well. One...read more

Dimension Therapeutics, which is developing novel, liver-directed gene therapies for rare genetic disorders, raised $72 million on Wednesday by offering 5.5 million shares at $13, below the range of $14 to $16. This gives the company a market cap of $355 million, 13.6% below the initial terms, and an enterprise value of $212 million. Insiders plan to buy up to $35 million of...read more